Early trials targeting antigens such as HER2 in glioblastoma and ovarian cancer, as well as ROBO-1 in pancreatic cancer, have shown encouraging results, including tumor regression and minimal toxicities. This evidence concerns the gene ERBB2 and ovarian cancer.